Retail

Walgreens Profit Misses Estimates On Pharmacy Weakness

Share this article

Drugstore chain Walgreens Boots Alliance Inc posted a quarterly profit that missed expectations on Wednesday, hurt by lower payments from insurers on drugs sold, sending shares down nearly 4% before the bell.

Sluggish retail growth, disappointing performance of Boots UK unit and low reimbursement rates for drugs have pushed Walgreens' shares down 15.3% in the last year, making it the worst performer on Dow Jones Industrials Average index.

Low Reimbursement Rates

Sales in the company's US retail pharmacies missed estimates, despite the company selling more prescription drugs, as continued low reimbursement rates ate into the unit's profit.

The unit's sales rose 1.6% to $26.1 billion (€23.46 billion), missing estimates of $26.18 billion (€23.53 billion), according to IBES data from Refinitiv. Gross profit from the unit fell 5.2%.

Excluding items, the company earned $1.37 per share, missing estimates of $1.41.

Net income attributable to Walgreens fell to $845 million (€759.58 million), or 95 cents per share, in the first quarter ended 30 November, from $1.12 billion (€1.01 billion), or $1.18 per share, a year earlier.

Revenue rose to $34.34 billion (€30.87 billion) from $33.79 billion (€30.37 billion).

News by ReutersClick subscribe to sign up to ESM: European Supermarket Magazine.

Stay Connected With Our Weekly Newsletter

Processing your request...

Thanks! please check your email to confirm your subscription.

By signing up you are agreeing to our Terms & Conditions and Privacy Policy
Enjoy unlimited digital access for 30 days
Get exclusive access to the latest grocery retail & FMCG news, interviews with industry leading executives, and expert analysis on the trends shaping the sector today
Enjoy unlimited digital access for 30 days
Enjoy unlimited digital access for 30 days
Get exclusive access to the latest grocery retail & FMCG news, interviews with industry leading executives, and expert analysis on the trends shaping the sector today
Enjoy unlimited digital access for 30 days

Copyright © 2022. All rights reserved. Developed by Square1 and powered by PublisherPlus.com